Stemtech Corp (STEK)
Stemtech Corporation is a pioneering company specializing in stem cell nutrition. It formulates scientifically-backed products designed to optimize the body's intrinsic stem cell physiology. With a market presence spanning the Americas, Latin America, and Asia, its offerings are engineered to bolster the natural functions of the body's stem cells. These solutions achieve this by stimulating the release of more stem cells, facilitating their efficient circulation through the bloodstream, and guiding their migration into various tissues. This process enables the stem cells to perform their continuous regenerative and repair tasks, crucial for maintaining optimal health and vitality. The company's comprehensive portfolio of dietary supplements includes prominent brands such as RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze. Stemtech Corporation's operations are headquartered in Miramar, Florida.
Sector: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Industry: Drug Manufacturers - Specialty & Generic
Stemtech Corporation
- Not computed: short interest % needs a single float figure, and the float on record is a bound or estimate.
- 147
- 1.00
The cost to borrow STEK shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 92.1%
- 657.5K
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 29, 2026 | 657.5K sh |
| Oct 28, 2026 | 657.5K sh |
| Sep 30, 2026 | 852.4K sh |
| Sep 29, 2026 | 852.4K sh |
| Sep 23, 2026 | 226.0K sh |
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 16, 2026 | 92.1% |
| Nov 13, 2026 | 90.4% |
| Nov 12, 2026 | 94.6% |
| Nov 11, 2026 | 25.8% |
| Nov 10, 2026 | 32.9% |
130 calendar days requested; 82 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for STEK: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 147 STEK shares were sold short (1.00 days to cover).